Research Article

Comprehensive Analysis of the Expression of TGF-β Signaling Regulators and Prognosis in Human Esophageal Cancer

Wei Song, Wei-Jie Dai, Meng-hui Zhang, Han Wang, and Xiao-Zhong Yang

Department of Gastroenterology, The Affiliated Huai’an No.1 People’s Hospital of Nanjing Medical University, Huai’an 223300, China

Correspondence should be addressed to Xiao-Zhong Yang; hayyyyyz@njmu.edu.cn

Received 18 August 2021; Revised 13 September 2021; Accepted 15 September 2021; Published 23 October 2021

Abstract

More and more evidences show that TGF-β has a crucial role in tumor initiation and development. However, the mechanism of the TGF-β signal regulator in esophageal cancer (EC) is still unclear. Here, we use a variety of bioinformatics methods to analyze the expression and survival data of TGF-β signal regulators in patients with EC. We extracted the expression of the S-TGF-β signal regulator from The Cancer Genome Atlas (TCGA). The cBioPortal database was used to assess the frequency of genetic variation. The TGF-β signal regulator is expressed in EC and normal tissues. The objective is to use the Kaplan-Meier plotter database to investigate the prognostic value of TGF-β signal regulators in cancer patients. The DAVID and clusterProfiler software package were used for functional enrichment analysis. We found that patients with TGF-β signaling mutations have shorter overall survival, disease-free survival, disease-specific survival, platinum overall survival, and platinum-free progression survival. We found that compared with the noncancerous tissues of patients with EC, ZFYVE9, BMPR1B, TGFB3, TGFBRAP1, ACVRL1, TGFBR2, SMAD4, SMAD7, ACVR2A, BMPR1, and SMAD9 were significantly downregulated in tumor tissues, while ACVR1 and Smad1 were significantly upregulated in tumor samples. Univariate survival analysis showed that ACVR1, TGFBR3, TGFBRAP1, BMPR1A, SMAD4, and TGFBR2 were positively correlated with overall survival (OS) prolongation. In addition, TGF-β signal transduction regulators could be divided into two classes. Subclass 1 was involved in regulating cell adhesion, PI3K-Akt signaling, and Rap1 signaling. Subclass 2 was related to regulating angiogenesis and PI3K signaling. In short, all members of TGF-β signal regulators can be used as biomarkers to predict the prognosis of patients with EC.

1. Background

Esophageal cancer (EC) is the eighth most common malignant tumor in the world, posing a great threat to public health [1, 2]. Esophageal squamous cell carcinoma (ESCC) has the characteristics of strong invasiveness, high metastasis rate, and poor prognosis [3]. It is reported to be the most common histological subtype of EC, accounting for nearly 80% of all EC incidences [4]. After 4 or 5 years of diagnosis, the 5-year survival rate of patients with EC is only 15-25% [4]. There is increasing evidence that some genetic and epigenetic changes contribute to the tumorigenesis of ESCC [5]. It is of great significance to find new therapeutic targets for ESCC.

TGF-β exerts its function in human cells. In a typical signaling, a TGF-β ligand binds to a heterotetrameric receptor complex including TGFBR1 and TGFBR2 [6]. Then, the ligand and receptor complex phosphorylated and activated downstream SMAD2/3, which is a component of a transcription factor [7]. The Smad complex then cooperates with other regulators to direct transcription activation and regulate multiple downstream mechanisms [8]. However, Smad7 could also suppress the activation of TGF-β/Smad signaling through competitively binding to TGFBR1 [9]. In addition, the TGF-β pathway could crosstalk with Rho, PI3K, and MAPK signaling to promote EMT, invasion, and angiogenesis [10]. Previous studies had demonstrated the important roles of TGF-β in human cancers. For instance, TGF-β modulates the cell cycle through the transcriptional regulation inhibitors p15INK4 and p21CIP1 [11]. In addition, the TGF-β/Smad axis also promotes cell stemness and mesenchymal transformation by upregulating multiple gene...
Figure 1: Continued.
Figure 1: Prognostic relevance of genomic alterations of TGF-β signal regulators in human cancers. (a–k) The prognosis of genomic alterations in multiple pathways was determined using TCGA esophageal adenocarcinoma datasets, including TGF-beta (a), survival and cell death (b), cell cycle (c), migration and invasion (d), DNA damage (e), NOTCH (f), KRAS (g), RTK (h), PI3K-AKT (i), ribosome (j), and angiogenesis (k).
Disease free (months)

(a)

Disease-specific

(b)

Platinum overall survival months

(c)

Figure 2: Continued.
expression, such as Snail and Vim [12]. Understanding the expression profile and potential functions of TGF-β signaling could provide novel clues to identify novel treatment markers for esophageal cancer.

To the best of our knowledge, a comprehensive analysis has yet to be applied to clarify the role of TGF-β signaling regulators in EC. Based on various bioinformatics databases, this study detected the RNA levels and mutation status of the TGF-β signal regulator in EC and predicted the potential functions of these regulators in EC.

2. Materials and Methods

2.1. TCGA Database. TCGA included the RNA sequence data of human genes in more than 30 cancer types. The expression profile of the TGF-β signal regulator is retrieved from TCGA database, and the clinicopathological information of EC patients are also downloaded from this database [13]. The receiver operating characteristic (ROC) [14] curve assesses the diagnostic value of the TGF-β signal regulator in EC patients.

2.2. cBioPortal Database. cBioPortal (https://www.cbioportal.org/) provides large-scale cancer genome data and was used to evaluate the frequency of TGF-β signal regulator mutations in EC patients [15].

2.3. Analysis of Correlation and Function Enrichment of the TGF-β Signal Regulator. The Corrplot [16] software package was used to analyze the Pearson correlation coefficient between the expression of the TGF-β signal regulator and other mRNAs. We used the Database for Annotation, Visualization and Integrated Discovery (DAVID) for the GO- and KEGG-enriched analysis and annotation database to comprehensively explore the potential biological significance of the list of genes of interest. The clusterProfiler software package of R software was used to visualize the enrichment results according to the P value (P < 0.05). In order to reveal the relationship between TGF-β signal regulators, we use the STRING database (https://string-db.org/) to build a PPI network [17].

2.4. Kaplan-Meier Plotter Database. The Proc software package [18] in the R software was used to analyze the ROC curve to explore the sensitivity and specificity of TGF-β signal regulators in EC. The Kaplan-Meier plotter (https://kmplot.com/) [19] is a database including microarray and TCGA gene expression data, which was used to analyze the correlation between TGF-β signal regulator expression and survival status in EC [20].

3. Results

3.1. Prognostic Relevance of Genomic Alterations in Patients with EC. In order to identify key pathways involved in regulating the progression of ESCC, we determined the prognosis of genomic alterations in multiple pathways using TCGA esophageal adenocarcinoma datasets, including TGF-beta, survival and cell death, cell cycle, migration and invasion, DNA damage, NOTCH, KRAS, RTK, PI3K-AKT, ribosome, and angiogenesis. We found that patients with mutations in TGF-beta, survival and cell death, cell cycle, migration and invasion, DNA damage, and NOTCH demonstrated worse prognosis compared with patients without mutated signaling (Figure 1).
| Gene   | %   | Status                      |
|--------|-----|-----------------------------|
| TGFB1  | 1.4% | Missense mutation (putative driver) |
| TGFB2  | 2.9% | Missense mutation (putative driver) |
| TGFB3  | 2.1% | Missense mutation (unknown significance) |
| TGFB1R1| 1.9% | Truncating mutation (putative driver) |
| TGFB2R2| 5%   | Truncating mutation (unknown significance) |
| TGFB3R3| 2.1% | No alterations |
| BMP2   | 1.9% | Inframe mutation (putative driver) |
| BMP3   | 2.7% | Inframe mutation (unknown significance) |
| BMP4   | 1.4% | Truncating mutation (putative driver) |
| BMP5   | 4%   | Truncating mutation (unknown significance) |
| BMP6   | 3%   | No alterations |
| BMP7   | 5%   | Missense mutation (putative driver) |
| GDF2   | 2.8% | Missense mutation (unknown significance) |
| BMP10  | 1.3% | Amplification |
| BMP15  | 4%   | Deep deletion |
| BMPR1A | 2.9% | Missense mutation (unknown significance) |
| BMPR1B | 2%   | Deep deletion |
| BMPR2  | 4%   | Missense mutation (putative driver) |
| ACVR1  | 1.4% | Truncating mutation (unknown significance) |
| ACVR1B | 2.2% | No alterations |
| ACVR1C | 1.4% | Missense mutation (unknown significance) |
| ACVR2A | 6%   | Deep deletion |
| ACVR2B | 1.7% | Deep deletion |
| ACVR1L | 2.2% | Deep deletion |
| NODAL  | 1.3% | No alterations |
| GDF1   | 1.2% | Missense mutation (unknown significance) |
| GDF11  | 1.9% | Deep deletion |
| INHA   | 1.4% | Deep deletion |
| INHBA  | 5%   | Missense mutation (unknown significance) |
| INHBB  | 4%   | Deep deletion |
| INHBC  | 1.7% | Deep deletion |
| INHBE  | 2.1% | Deep deletion |
| SMAD2  | 4%   | Deep deletion |
| SMAD3  | 2%   | Deep deletion |
| SMAD1  | 1.8% | Missense mutation (unknown significance) |
| SMAD5  | 1.8% | Missense mutation (unknown significance) |
| SMAD4  | 12%  | Missense mutation (unknown significance) |
| SMAD9  | 4%   | Missense mutation (unknown significance) |
| SMAD6  | 1.6% | Amplification |
| SMAD7  | 5%   | Missense mutation (unknown significance) |
| SPTBN1 | 2.8% | Amplification |
| TGFBRAP1| 3% | Amplification |
| ZFYVE9 | 1.7% | Amplification |

(a) Figure 3: Continued.
Alteration frequency

- 20%
- 40%
- 60%

Mutation data
- + + + + + + +

CNA data
- + + + + + + +

(b) Figure 3: Continued.
Of note, we observed that TGF-beta was most significantly associated with the overall survival time in EC. To further confirm the prognostic value of TGF-beta signaling, we analyzed the correlation between mutations in this signaling and disease-free survival time (Figure 2(a)), disease-specific survival time (Figure 2(b)), platinum overall survival time (Figure 2(c)), and platinum progression free survival time (Figure 2(d)). As expected, we found that patients with mutations in TGF-beta signaling were significantly associated with shorter survival time compared to that without these mutations.

3.2. Genetic Alteration Differences of TGF-β Signaling Regulators in EC Patients. Furthermore, genetic alteration of TGF-β signaling regulators in EC was analyzed using the cBioPortal database, which included 1443 patients from seven related studies. The mutation, amplification, and deep deletion were the most common types of alteration in different EC subtypes (Figure 3(a)). We also observed that TGF-β signaling regulators were altered in 19% of EC patients (254/1354) (Figure 3(b)). The mutation rates of TGF-β signaling regulators for EC ranged from 0.8% to 12% for individual genes (SMAD4, 12%; SMAD7, 5%; ACVR2A, 6%; TGFBR2, 5%; BMP7, 5%; BMP5, 4%; BMP15, 4%; and BMPR2, 4%) (Figure 3(c)).

3.3. Relative Transcriptional Expression of TGF-β Signaling Regulators in EC Patients. Comparison of the RNA levels of TGF-β signaling regulators in EC and noncancer samples showed that RNA levels of ZFYVE9, BMPR1B, TGFB3, TGFBRAP1, ACVR1, TGFBR2, SMAD4, SMAD7, ACVR2A, BMPR1A, SMAD9, and TGFBR3 were significantly downregulated in EC tumor samples compared to normal samples; however, ACVR1 and SMAD1 were upregulated in EC samples (Figure 4).

3.4. Diagnostic Value of TGF-β Signaling Regulators for Distinguishing EC Patients. To investigate the prognostic value of TGF-β signaling regulators in EC, we applied a ROC curve analysis using TCGA database (Figure 5). ROC analysis of TGF-β signaling regulators revealed that these regulators had high diagnostic value for distinguishing EC from normal individuals, including ACVR1 (0.7720), ACVR1L (0.6865), ACVR2A (0.7789), SMAD1 (0.7219), SMAD7 (0.7356), SMAD4 (0.8550), SMAD9 (0.8349), BMPR1A (0.6791), BMPR1B (0.7681), and TGFBRAP1.
Figure 4: Relative transcriptional expression of TGF-β signaling regulators in EC patients. (a) Heatmap showed the comparison of the RNA levels of TGF-β signaling regulators in EC and noncancer samples. (b) ZFYVE9, BMPR1B, TGFB3, TGFBRAPI, ACVRL1, TGFB2, SMAD4, SMAD7, ACVR2A, BMPR1A, SMAD9, and TGFB3 were significantly downregulated in EC tumor samples compared to normal samples; however, ACVR1 and SMAD1 were upregulated in EC samples.
| Gene   | Area   | Std. error | 95% confidence interval | P value |
|--------|--------|------------|-------------------------|---------|
| ACVR1  | 0.7720 | 0.06712    | 0.6404 to 0.9036        | 0.002472|
| ACVRL1 | 0.6865 | 0.09168    | 0.5068 to 0.8662        | 0.03792 |
| ACVR2A | 0.7789 | 0.06164    | 0.6580 to 0.8997        | 0.001914|
| SMAD1  | 0.7219 | 0.04636    | 0.6310 to 0.8127        | 0.01354 |

Figure 5: Continued.
Figure 5: Continued.
Figure 5: Continued.
3.5. The Dysregulation of TGF-β Signaling Regulators Correlated with Longer Survival Time in EC. Our results showed upregulation of ACVR1, TGFBR3, TGFBRAP1, BMPR1A, SMAD4, and TGFBR2 associated with a short overall survival time in patients with EC (Figure 6).

3.6. Construction of the Protein-Protein Interaction Network Regulated by Hub TGF-β Signaling Regulators in EC. In order to investigate the potential mechanism of TGF-β signaling regulators in EC, we applied coexpression network analysis using the cBioPortal database and PPI network using the STRING database in ESCC. The correlation among ACVR1, ACVRL1, ACVR2A, SMAD1, SMAD7, SMAD4, SMAD9, BMPR1A, BMPR1B, TGFBRAP1, TGFBR2, TGFBR3, TGFB3, and ZFYVE9 is shown in Figure 7. The results showed that these hub genes could be divided into two subclasses, including subclass 1 (ACVR1, SMAD1, ZFYVE9, BMPR1B, and TGFB3) and subclass 2 (TGFBRAP1, ACVR1, TGFBR2, SMAD4, SMAD7, ACVR2A, BMPR1A, SMAD9, and TGFBR3). The coexpressed genes with Spearman’s correlation > 0.8 were selected as the potential targets of hub genes in ESCC. The PPI network is shown in Figure 6. Based on PPI network analysis, we revealed several key targets of TGF-β signaling regulators in EC, including KDR, ACVR2A, PRRX1, ACVRL1, TGFBRAP1, GDF6, BMPR1B, ENG, CD, TGFBR2, SMAD4, SMAD7, FN1, SMAD1, ZFYVE9, ACVR1, TGFB3, VWF, SMAD9, BMPR1A, and TGFBR3.

3.7. Functional Enrichment Analysis of TGF-β Signaling Regulators. To investigate the functional roles in EC, we constructed the correlation between the expression of TGF-β signaling regulators, PPI network, GO analysis, and KEGG enrichment analysis (Figure 8). GO analysis showed that ACVR1, SMAD1, ZFYVE9, BMPR1B, and TGFB3 were related to regulating cell adhesion, extracellular matrix organization, collagen fiber organization, endodermal cell differentiation, angiogenesis, negative regulation of chondrocyte differentiation, extracellular matrix disassembly, integrin-mediated signaling pathway, and wound healing. And subclass 2 was related to regulating angiogenesis, cell adhesion, extracellular matrix organization, positive regulation of GTPase activity, signal transduction, PI3K signaling, Rho signal transduction, calcium ion transport, leukocyte migration, vasculogenesis, and peptidyl-tyrosine phosphorylation.

KEGG analysis showed that ACVR1, SMAD1, ZFYVE9, BMPR1B, and TGFB3 were related to regulating proteoglycan in cancer, focal adhesion, tight junction, PI3K-Akt signaling pathway, cell adhesion molecules (CAMs), Rap1 signaling pathway, osteoclast differentiation, and Hippo signaling pathway. And subclass 2 was related to regulating angiogenesis, cell adhesion, extracellular matrix organization, positive regulation of GTPase activity, signal transduction, PI3K signaling, Rho signal transduction, calcium ion transport, leukocyte migration, vasculogenesis, and peptidyl-tyrosine phosphorylation.

4. Discussion

Previous studies had revealed that multiple oncogenetic pathways were related to the tumorigenesis and...
Figure 6: The dysregulation of TGF-β signaling regulators correlated with longer survival time in EC. (a–f) Our results showed upregulation of ACVR1 (a), TGFBR3 (b), TGFBRAP1 (c), BMPR1A (d), SMAD4 (e), and TGFBR2 (f) associated with a short overall survival time in patients with EC.
Figure 7: Continued.
development of EC, such as TGF-beta, survival and cell death, cell cycle, migration and invasion, DNA damage, NOTCH, KRAS, RTK, PI3K-AKT, ribosome, and angiogenesis signaling. For example, in a normal esophagus, NOTCH regulates the development of the esophageal squamous epithelium [21]. In ESCC, NOTCH plays either a tumor suppressive or an oncogenetic role [21]. Activation of KRAS induces the AKT-mTOR or RAF-ERK-pathways, which have an important role in modulating tumor microenvironment in EC [22]. Angiogenesis has a fundamental role in cancer growth and metastasis [23]. In EC, increased angiogenesis regulator expression was reported to be related to worse response and prognosis of EC. In this study, as far as we know, we used various large databases including TCGA, GEO, STRING, and Kaplan-Meier plotter, for the first time to analyze the level, gene changes, and functions of TGF-beta signal regulators in patients with esophageal cancer. Our results showed that the TGF-beta signal plays an important role in the diagnosis of EC. ROC analysis showed that most TGF-beta signal regulators have high diagnostic value in distinguishing EC from normal patients. KM analysis showed that ACVR1, TGFB3, TGFBRAP1, BMPR1A, SMAD4, and TGFB3 were positively correlated with OS prolongation. In addition, all TGF-beta signal transduction regulators are closely related to multiple biological processes, including cell adhesion, extracellular matrix tissue, collagen catabolism, and PI3K signaling. In short, the members of TGF-beta signal regulators can be potential biomarkers for the prediction of treatment and prognosis of EC. More and more evidences indicate that TGF-beta plays a key role in tumor cells and switches its function between tumor suppression and tumor promotion phenotypes [24]. For instance, TGF-beta could arrest the cell cycle via CREB to mediate the histone acetylation of PAI-1 in a p53/Smad-dependent manner [25]. In addition, TGF-beta can activate FoxO1 to induce the expression of p21cip1 to induce the G0/G1 arrest [11]. However, the role of the TGF-beta factor in esophageal squamous cell carcinoma needs further study.

**Figure 7:** Construction of the protein-protein interaction network regulated by hub TGF-beta signaling regulators in EC. (a) The correlation among ACVR1, ACVRL1, ACVR2A, SMAD1, SMAD7, SMAD4, SMAD9, BMPR1A, BMPR1B, TGFBRAP1, TGFB2, TGFB3, and ZFYVE9 was shown. (b) The PPI network was constructed to show the interaction among KDR, ACVR2A, PRRX1, ACVRL1, TGFBRAP1, GDF6, BMPR1B, ENG, CD, TGFB2, SMAD4, SMAD7, FN1, SMAD1, ZFYVE9, ACVR1, TGFB3, VWF, SMAD9, BMPR1A, and TGFB3.
Activation of phospholipase C activity
Positive regulation of Rho protein signal transduction
Positive regulation of MAP kinase activity
Positive regulation of T cell proliferation
Vasculogenesis
Defense response
Calcium ion transport
Muscle contraction
Chemotaxis
Leukocyte migration
Single organismal cell-cell adhesion
Muscle contraction
Calcium ion transport
Positive regulation of phosphatidylinositol 3-kinase signaling
Defense response
Vasculogenesis
Positive regulation of T cell proliferation
Positive regulation of MAP kinase activity
Positive regulation of Rho protein signal transduction
Activation of phospholipase C activity

Figure 8: Continued.
Staphylococcus aureus infection
Platelet activation
Vascular smooth muscle contraction
Calcium signaling pathway
Focal adhesion
Ras signaling pathway
Rap1 signaling pathway
Cell adhesion molecules (CAMs)
PI3K-akt signalling pathway
cGMP-PKG signaling pathway
Calcium signaling pathway
Vascular smooth muscle contraction
Platelet activation
Staphylococcus aureus infection
Q value

Figure 8: Continued.
Negative regulation of chondrocyte differentiation
Chondroitin sulfate biosynthetic process
Endodermal cell differentiation
Cellular response to amino acid stimulus
Collagen fibril organization
Extracellular matrix disassembly
Wound healing
Cell-matrix adhesion
Axon guidance
Regulation of cell shape
Integrin-mediated signaling pathway
Axonogenesis
Cell-matrix adhesion
Wound healing
Extracellular matrix disassembly
Collagen fibril organization
Cellular response to amino acid stimulus
Endodermal cell differentiation
Chondroitin sulfate biosynthetic process
Positive regulation of ERK1 and ERK2 cascade
Positive regulation of cell migration
Skeletal system development
Angiogenesis
Inflammatory response
Axonogenesis
Cell-matrix adhesion
Wound healing
Extracellular matrix disassembly
Collagen fibril organization
Cellular response to amino acid stimulus
Endodermal cell differentiation
Chondroitin sulfate biosynthetic process
Negative regulation of chondrocyte differentiation

Figure 8: Continued.
Compared with TGF-β-mutant patients, we did find a worse prognosis in TGF-β-wild-type patients. In addition, we found that patients with TGF-β signaling mutations were significantly associated with shorter disease-free survival, disease-specific survival time, platinum overall survival time, and platinum progression-free survival time. Further analysis showed that ZFYVE9, BMPR1B, TGFB3, TGFBRAP1, ACVRL1, TGFBR2, SMAD4, SMAD7, ACVR2A, and BMPR1AEC patients had significantly lower expression, while ACVR1 and SMAD1 were expressed higher in EC than in normal samples. Thus, we showed that TGF-β regulators have high diagnostic capacity in distinguishing EC patients from healthy donors. To further clarify the genetic alteration of TGF-β signaling regulators, we analyzed the cBioPortal database and found that the percentages of genetic alterations in TGF-β signaling regulators for EC varied from 0.8 to 14% for individual genes.

Of note, our results showed upregulation of ACVR1, TGFBR3, TGFBRAP1, BMPR1A, SMAD4, and TGFBR2 associated with a short overall survival time in patients with EC. ACVR1 is an activin type I receptor including 509 amino acids [26]. The ACVR1 was found to be expressed in multiple human tissues and cell lines using RNA sequencing data. ACVR1 is a member of the BMP/TGFβ receptor family [26]. ACVR1 forms a heterotetrmeric receptor complex with BMPR2, ACVR2A, and ACVR2B [27]. When the signaling was activated, the type I receptor is trans-phosphorylated by the type II receptor. As a result, the kinase domain of the ACVR1 is activated and then phosphorylated the Smad1/5/8 protein [28]. In addition to the typical Smad signaling pathway, ACVR1 can also activate noncanonical signaling. New research shows that ACVR1 plays an important role in human cancer. For example, constitutively active mutants of ALK2 have been identified as the cause of FOP and were related to DIPG progression via modulating BMP signaling [29]. In pancreatic cancer, ACVR1 was found to regulate the stem cells and tumorigenicity of pancreatic cancer cells [30]. Deregulated ACVR1 was reported to be related to gastric cancer progression [31]. ACVR1 is significantly increased in esophageal tumors. In ESCC, the increase in the number of repeated copies of ACVR1 and the corresponding transcriptional overexpression are associated with the survival rate of patients with ESCC. In ESCC, TGFBR3 is an independent unfavourable prognostic marker and positively correlated with Ki-67 [32]. The key roles of SMAD4 in ESCC had been demonstrated in several previous reports. For example, Smad4 loss is associated with an increased propensity for disease recurrence and poor survival in EC, and Smad4 protein level was correlated with the depth of invasion of ESCC [33]. Smad7 is an inhibitory factor of the TGF-beta superfamily which was reported to be inversely correlated with depth of invasion of EC [34]. Our study for the first time comprehensively analyzed the prognostic value of these genes in EC.

**Figure 8:** Functional enrichment analysis of TGF-β signaling regulators: (a, b) the GO and KEGG analysis of subclass 1 genes; (c, d) the GO and KEGG analysis of subclass 2 genes.
To investigate the potential mechanism of TGF-β signal regulators in EC, we applied coexpression network analysis using the cBioPortal database and PPI network using the STRING database in ESCC. The results showed that these hub genes could be divided into two subclasses, including subclass 1 (ACVR1, SMAD1, ZFYVE9, BMPR1B, and TGFBR3) and subclass 2 (TGFBRAP1, ACVR1L, TGFBR2, SMAD4, SMAD7, ACVR2A, BMPR1A, SMAD9, and TGFBR3). Subclass 1 was involved in regulating cell adhesion, wound healing, PI3K-Akt signaling pathway, and Hippo signaling pathway. Of note, several previous studies had indicated that the hub genes in subclass 1 were related to the regulation of these signalings. For example, the activation of the intracellular BMP-Smad1/5 pathway regulated the expression of matrix macromolecules aggrecan and collagen II [35]. Subclass 2 was involved in regulating angiogenesis, cell adhesion, cGMP-PKG signaling, and PI3K-Akt signaling. Emerging studies demonstrated that the abnormal regulation of these signalings was observed in multiple tumors and related to tumor initiation and metastasis [36]. For example, the Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in EC [37]. Targeting the Hippo coactivator YAP1 through BET bromodomain inhibition could suppress EC growth [38]. Of note, various studies had indicated that TGF-β signaling was cross talked with these signalings in human cancers. For example, TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability [39]. PI3K/mTORC2 could regulate TGF-β/activin signalings by modulating Smad2/3 activity [40]. In triple negative breast cancer, TGF-β promotes noncanonical PI3K/Akt signaling by reducing PTEN [41]. In addition, TGF-β targets the Hippo pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear translocation [42]. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth [43]. Therefore, we hypothesized that the mechanism of the TGF-β signal regulator is to induce tumorigenesis and development by regulating these pathways. This provides new ideas for the diagnosis and treatment of EC.

Inevitably, this study had several limitations. First, most of the findings in this study were obtained using public databases. The biological functions of TGF-β regulators were unclear, and more experimental validation is needed to further confirm their functional importance in the EC. Second, TCGA database was used in this study. Further studies integrating multimics datasets might strengthen the findings of this study. Third, the clinical information of the patients was limited. Thus, collecting more clinical samples to confirm the expression and mutation profile of TGF-β regulators is still needed.

5. Conclusions

In conclusion, TGF-β signal regulators are abnormally expressed in EC. The high expression of ACVR1, TGFBR3, TGFBRAP1, BMPR1A, Smad4, and TGFBR2 is positively correlated with prolongation of OS. These genes play a key role in EC and improve the survival rate and prognosis of the EC marker of accuracy.

Data Availability

The expression profile of the TGF-β signal regulator is retrieved from TCGA-ESCA database, and the clinicopathological information of EC patients is also downloaded from this database.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Wei Song and Wei-Jie Dai contributed equally to this work.

References

[1] C. C. Wu and C. J. Chen, “Esophageal carcinoma,” The New England Journal of Medicine, vol. 372, no. 15, pp. 1470–1473, 2015.
[2] C. Gu, X. Shi, C. Dai et al., “RNA m6A modification in cancers: molecular mechanisms and potential clinical applications,” The Innovation, vol. 1, no. 3, article 100066, 2020.
[3] M. Emi, J. Hihara, Y. Hamai, T. Furukawa, Y. Iibu, and M. Okada, “Clinicopathologic features of submucosal esophageal squamous cell carcinoma,” The Annals of Thoracic Surgery, vol. 104, no. 6, pp. 1858–1864, 2017.
[4] H. Liang, J. H. Fan, and Y. L. Qiao, “Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China,” Cancer Biology & Medicine, vol. 14, no. 1, pp. 33–41, 2017.
[5] K. Ma, B. Cao, and M. Guo, “The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma,” Clinical Epigenetics, vol. 8, no. 1, p. 43, 2016.
[6] F. T. Lee, A. J. Mountain, M. P. Kelly et al., “Enhanced efficacy of radioimmunotherapy with90Y-CHX-A-189DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478,” Clinical Cancer Research, vol. 11, no. 19, pp. 7080s–7086s, 2005.
[7] A. Hata and Y. G. Chen, “TGF-β signaling from receptors to Smads,” Cold Spring Harbor Perspectives in Biology, vol. 8, no. 9, article a022061, 2016.
[8] C. S. Hill, “Transcriptional control by the SMADs,” Cold Spring Harbor Perspectives in Biology, vol. 8, no. 10, article a022079, 2016.
[9] X. Yan, Z. Liu, and Y. Chen, “Regulation of TGF-beta signaling by Smad7,” Acta biochimica et biophysica Sinica, vol. 41, no. 4, pp. 263–272, 2009.
[10] K. Luo, “Signaling cross talk between TGF-β/Smad and other signaling pathways,” Cold Spring Harbor Perspectives in Biology, vol. 9, no. 1, article a022137, 2017.
[11] Y. Zhang, P. B. Alexander, and X. F. Wang, “TGF-β family signaling in the control of cell proliferation and survival,” Cold Spring Harbor Perspectives in Biology, vol. 9, no. 4, article a022145, 2017.
[12] V. W. Xue, J. Y. Chung, C. A. G. Córdoba et al., “Transforming growth factor-β: a multifunctional regulator of cancer immunity,” Cancers, vol. 12, no. 11, p. 3099, 2020.

[13] N. Cancer Genome Atlas, “Comprehensive genomic characterization of head and neck squamous cell carcinomas,” Nature, vol. 517, no. 7536, pp. 576–582, 2015.

[14] G. B. Peers, D. Kloth, D. B. Downey, S. Dunlavy, and J. L. Chin, “Receiver operating characteristic (ROC) curve analysis of transrectal ultrasonographic prostate cancer detection,” The Canadian Journal of Urology, vol. 4, no. 1, pp. 293–299, 1997.

[15] J. Gao, B. A. Aksoy, U. Dogrusoz et al., “Integrative analysis of complex cancer genomics and clinical profiles using the cbioPortal,” Science Signaling, vol. 6, no. 269, p. p1i, 2013.

[16] C. Pesenti, S. E. Navone, L. Guarinaccia et al., “The genetic landscape of human glioblastoma and matched primary cancer stem cells reveals intratumour similarity and intratumour heterogeneity,” Stem Cells International, vol. 2019, Article ID 2617030, 12 pages, 2019.

[17] C. Gu, J. Chen, X. Dang et al., “Hipppharyn focusing core genes based prognostic signature and immune infiltration patterns in lung squamous cell carcinoma,” Frontiers in Oncology, vol. 11, p. 1486, 2021.

[18] X. Robin, N. Turck, A. Hainard et al., “pROC: an open-source package for R and S+ to analyze and compare ROC curves,” BMC Bioinformatics, vol. 12, no. 1, p. 77, 2011.

[19] C. Gu, X. Shi, W. Qiu et al., “Comprehensive analysis of the prognostic role and mutational characteristics of m6A-related genes in lung squamous cell carcinoma,” Frontiers in Cell and Development Biology, vol. 9, article 661792, 2021.

[20] A. Nagy, A. Lanczky, L. Guarnaccia et al., “Validation of miRNA prognostic power in hepatocellular carcinoma, a multifunctional regulator of cancer immunity,” Canadian Journal of Urology, vol. 4, no. 1, pp. 293–299, 2011.

[21] V. W. Xue, J. Y. Chung, C. A. G. Córdoba et al., “The role of Hippo-YAP signaling in squamous cell carcinoma,” Cancer Journal, vol. 21, no. 4, pp. 267–273, 2015.

[22] P. Papageorgis, “TGFB signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis,” Journal of Oncology, vol. 2015, Article ID 587193, 15 pages, 2015.

[23] Y. Kawarada, Y. Inoue, F. Kawasaki et al., “TGFB induces p53/Smads complex formation in the PAI-1 promoter to activate transcription,” Scientific Reports, vol. 6, no. 1, article 35483, 2016.

[24] J. A. Valer, Sánchez-de-Diego, C. Pimenta-Lopes, J. L. Rosa, and F. Ventura, “ACVR1 function in health and disease,” Cell, vol. 8, no. 11, p. 1366, 2019.

[25] S. Aykul, R. A. Corpina, E. J. Goebel et al., “Activin A forms a non-signaling complex with ACVR1 and type II activin/BMP receptors via its finger 2 tip loop,” eLife, vol. 9, article e54582, 2020.

[26] J. Haupt, M. Xu, and E. M. Shore, “Variable signaling activity by FOP ACVR1 mutations,” Bone, vol. 109, pp. 232–240, 2018.

[27] M. Paciﬁci and E. M. Shore, “Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders,” Cytokine & Growth Factor Reviews, vol. 27, pp. 93–104, 2016.

[28] X. B. Wu, X. Feng, Q. M. Chang et al., “Cross-talk among AFAQ/A1, ACVR and microRNA-384 regulates the stemness of pancreatic cancer cells and tumorigenicity in nude mice,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 107, 2019.

[29] Z. Sun, C. Liu, W. G. Jiang, and L. Ye, “Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer,” Computational and Structural Biotechnology Journal, vol. 18, pp. 177–188, 2020.

[30] X. Zhang, Y. Chen, Z. Li, X. Han, and Y. Liang, “TGFB3 is an independent unfavourable prognostic marker in oesophageal squamous cell cancer and is positively correlated with Ki-67,” International Journal of Experimental Pathology, vol. 101, no. 6, pp. 223–229, 2020.

[31] A. D. Singh, T. J. Foxwell, K. Nason et al., “Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival,” The American Journal of Surgical Pathology, vol. 39, no. 4, pp. 487–495, 2015.

[32] H. Osawa, M. Nakajima, H. Kato, M. Fukushima, and H. Kuvano, “Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma,” Anticancer Research, vol. 24, no. 6, pp. 3703–3709, 2004.

[33] Z. Wang, S. S. Kim, W. C. Hutton, and S. T. Yoon, “E-cadherin upregulates expression of matrix macromolecules aggrecan and collagen II in the intervertebral disc cells through activation of the intracellular BMP–Smad1/5 pathway,” Journal of Orthopaedic Research, vol. 30, no. 11, pp. 1746–1752, 2012.

[34] T. Maehama, N. Nishio, J. Otani, T. W. Mak, and A. Suzuki, “The role of hippo-YAP signaling in squamous cell carcinoma,” Cancer Science, vol. 112, no. 1, pp. 51–60, 2021.

[35] S. Song, S. Honjo, J. Jin et al., “The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer,” Clinical Cancer Research, vol. 21, no. 11, pp. 2580–2590, 2015.

[36] S. Song, Y. Li, Y. Xu et al., “Targeting hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma,” Molecular Oncology, vol. 14, no. 6, pp. 1410–1426, 2020.

[37] W. T. Liu, K. Y. Huang, M. C. Lu et al., “TGFB-β upregulates the translation of USP15 via the PI3K/akt pathway to promote p53 stability,” Oncogene, vol. 36, no. 19, pp. 2715–2723, 2017.

[38] J. S. Yu, T. S. Ramasamy, N. Murphy et al., “PI3K/mTORC2 regulates TGFB-β/activin signalling by modulating Smad2/3 activity via linker phosphorylation,” Nature Communications, vol. 6, no. 1, p. 7212, 2015.

[39] P. K. Singh, S. Pandeswara, H. Geng, R. Lan, M. A. Venkatachalam, and P. Saikumar, “TGFB-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer,” Genes & Cancer, vol. 5, no. 9-10, pp. 320–336, 2014.

[40] D. E. Pefani, D. Pankova, A. G. Abraham et al., “TGFB-β targets the Hippo pathway scaffold RASSF1A to facilitate YAP/S-MAD2 nuclear translocation,” Molecular Cell, vol. 63, no. 1, pp. 156–166, 2016.

[41] M. Fuji, T. Toyoda, H. Nakashiki et al., “TGFB-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth,” The Journal of Experimental Medicine, vol. 209, no. 3, pp. 479–494, 2012.